Biological disease-modifying anti-rheumatic drugs with a focus on rituximab in achieving remission and low disease activity in patients with rheumatoid arthritis and psoriatic arthritis

Preview format:

Object preview unavailable

We use files, through the cookie quality improvement layer of our website.For more information, please read the document